B-cell lymphoma – Medxy AI

Breaking Ferroptosis Resistance: PRMT5 Inhibition Emerges as a Game-Changer in B-Cell Lymphoma Therapy

By MedXY 04/21/2026

PRMT5 inhibition sensitizes B-cell lymphomas to ferroptosis by disrupting the PRMT5-ATF5-SLC7A11 axis, offering a novel therapeutic strategy for relapsed or refractory disease.

Clinical Updates Hematology-Oncology news

Clinical Evolution of Axicabtagene Ciloleucel: From Salvage Therapy to Second-Line Standard of Care

By MedXY 01/13/2026

This review synthesizes clinical trial evidence for Axicabtagene Ciloleucel, tracing its development from refractory B-cell lymphoma to its current role as a second-line standard and its expansion into indolent and mantle cell lymphomas.

Hematology-Oncology Specialties

T-ICAHT: A New Grading System for Thrombocytopenia After CAR T-cell Therapy with Prognostic Significance

By MedXY 08/29/2025

A novel grading system, T-ICAHT, quantifies thrombocytopenia after CAR T-cell therapy, revealing its prevalence and prognostic impact, highlighting its value in patient management and outcome prediction across hematologic malignancies.

$Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study$

Clinical Updates news Oncology Specialties

Off-the-Shelf iPSC-Derived Natural Killer Cell Therapy for Relapsed or Refractory B-Cell Lymphoma: Key Evidence from a Multicentre Phase 1 Study

By MedXY 08/02/2025

FT516, an iPSC-derived NK cell therapy, shows promising safety and efficacy in relapsed or refractory B-cell lymphoma, potentially overcoming key limitations of existing cell therapies.